Ep 70: Best of ASCO colon.... 2025 ;)

You wanted it, we gave it... best of ASCO ...colon...2025 :D In this episode, hosts James and Sapna discuss the key highlights from ASCO 2025, focusing on significant abstracts related to melanoma treatment. They delve into the implications of adrenal insufficiency, the 5 year, final results of Lifileucel, and the ongoing debate between neoadjuvant and adjuvant therapies. The conversation also explores the role of IL-6 in treatment efficacy and the importance of understanding sentinel lymph node positivity. The hosts emphasize the need for innovative clinical trial designs to adapt to emerging data and improve patient outcomes.KeywordsASCO 2025, melanoma, neoadjuvant therapy, adrenal insufficiency, lifileucel, immunotherapy, clinical trials, IL-6, treatment outcomes, cancer researchChapters00:00 Introduction and Overview of ASCO 202503:16 DoorDash!05:43 Key Highlights from ASCO 202508:29 Lifileucel and Its Impact on Treatment10:53 Long-term Outcomes and Toxicity Considerations15:49 Exploring Treatment Efficacy in Refractory Populations17:41 Neoadjuvant and Adjuvant Therapies: A Comparative Analysis21:07 Investigating GM-CSF's Role in Mitigating Toxicity22:36 RELA 098: Insights and Implications25:37 Understanding Sentinel Lymph Node Positivity in Melanoma26:34 Future Directions in Neoadjuvant Therapy Research36:18 Fact Check38:17 Discussion on IPI GM-CSF and Adrenal Insufficiency42:09 Impact of Adrenal Insufficiency on Patients45:06 Future Directions in Neoadjuvant Trials47:26 Wrap-Up and Reflections